SCHEMBL23926517

SCHEMBL23926517

COc1ccc(C(=O)Nc2noc3ccc(NC(=O)OC(C)(C)C)cc23)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 8/20 0.61
SMN1; SMN2 Q16637 8/20 0.61
MAPT P10636 4/20 0.61
THRB P10828 1/20 0.46
NPC1 O15118 8/20 0.46
RAB9A P51151 8/20 0.46
ALOX15 P16050 1/20 0.45
HIF1A Q16665 1/20 0.45
ALDH1A1 P00352 3/20 0.45
NAMPT P43490 1/20 0.44
PKM P14618 2/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
GAA P10253 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22130273 0.80 TP53 (0.44) TP53SMN1; SMN2MAPTALOX15ALDH1A1
SCHEMBL30123600 0.80 TP53 (0.44) TP53SMN1; SMN2MAPTALOX15ALDH1A1
SCHEMBL22130267 0.79 TP53 (0.70) TP53SMN1; SMN2MAPTTHRBNPC1
SCHEMBL7079625 0.78 RAB9A (0.73) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL31377136 0.78 TP53 (0.44) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL22130137 0.78 RAB9A (0.47) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL23926493 0.78 SMN1; SMN2 (0.46) TP53SMN1; SMN2MAPTTHRBNPC1
SCHEMBL24705961 0.77 TP53 (0.58) TP53SMN1; SMN2MAPTTHRBNPC1
SCHEMBL31377141 0.77 TP53 (0.42) TP53SMN1; SMN2MAPTNPC1RAB9A
SCHEMBL17307569 0.77 CA12 (0.54) NAMPTCYP1A2CA12CA1CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2026-03-31 US disclosed
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2022-12-15 US disclosed
CN-113727972-A Novel hydrazone derivatives in which terminal amino group is substituted with aryl or heteroaryl group, and use thereof 韩国科学技术研究院 2021-11-30 CN disclosed
EP-3901139-A1 NOVEL HYDRAZONE DERIVATIVE WITH ARYL OR HETEROARYL GROUP SUBSTITUTED AT TERMINAL AMINE GROUP THEREOF AND USE THEREOF Korea Institute of Science and Technology (KR) 2021-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12590071-B2 Hydrazone derivative in which terminal amine group is substituted with aryl group or heteroaryl group, and use thereof ABL1, TH, CYP3A43 TP53 3499/4885SMN1; SMN2 4531/4885MAPT 3633/4885
US-20220396553-A1 NOVEL HYDRAZONE DERIVATIVE IN WHICH TERMINAL AMINE GROUP IS SUBSTITUTED WITH ARYL GROUP OR HETEROARYL GROUP, AND USE THEREOF AANAT, NAT1, HNMT TP53 4376/4885SMN1; SMN2 4864/4885MAPT 3061/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.